• 已选条件:
  • × Ashraf Dallol
  • × 期刊论文
  • × Journal of Translational Medicine
 全选  【符合条件的数据共:4条】

Journal of Translational Medicine,

Javaid I Sheikh, Ashraf Dallol, Ravinder Mamtani, Lotfi Chouchane

英文

预览  |  原文链接  |  全文  [ 浏览:3 下载:0  ]    

Journal of Translational Medicine,2016年

Mohammed H. Al-Qahtani, Abdelbaset Buhmeida, Rola Turki, Jaudah Al-Maghrabi, Rania Alam, Atlal Abusanad, Shadi Al-Khayyat, Mahmoud Shaheen Al-Ahwal, Huda Banni, Ashraf Dallol, Adel M. Abuzenadah, Osama Bajouh, Hani A. Alhadrami, Mohammed Abuzenadah, Aisha Elaimi

LicenseType:CC BY |

预览  |  原文链接  |  全文  [ 浏览:0 下载:0  ]    

BackgroundColorectal cancer (CRC) is a heterogeneous disease with different molecular characteristics associated with many variables such as the sites from which the tumors originate or the presence or absence of chromosomal instability. Identification of such variables, particularly mutational hotspots, often carries a significant diagnostic and/or prognostic value that could ultimately affect the therapeutic outcome.MethodsHigh-throughput mutational analysis of 99 CRC formalin-fixed and paraffin-embedded (FFPE) cases was performed using the Cancer Hotspots Panel (CHP) v2 on the Ion Torrent™ platform. Correlation with survival and other Clinicopathological parameters was performed using Fisher’s exact test and Kaplan–Meier curve analysis.ResultsTargeted sequencing lead to the identification of frequent mutations in TP53 (65 %), APC (36 %), KRAS (35 %), PIK3CA (19 %), PTEN (13 %), EGFR (11 %), SMAD4 (11 %), and FBXW7 (7 %). Other genes harbored mutations at lower frequency. EGFR mutations were relatively frequent and significantly associated with young age of onset (p = 0.028). Additionally, EGFR or PIK3CA mutations were a marker for poor disease-specific survival in our cohort (p = 0.009 and p = 0.032, respectively). Interestingly, KRAS or PIK3CA mutations were significantly associated with poor disease-specific survival in cases with wild-type TP53 (p = 0.001 and p = 0.02, respectively).ConclusionsFrequent EGFR mutations in this cohort as well as the differential prognostic potential of KRAS and PIK3CA in the presence or absence of detectable TP53 mutations may serve as novel prognostic tools for CRC in patients from the Kingdom of Saudi Arabia. Such findings could help in the clinical decision-making regarding therapeutic intervention for individual patients and provide better diagnosis or prognosis in this locality.

    Journal of Translational Medicine,2011年

    Ashraf Dallol, Lotfi Chouchane, Javaid I Sheikh, Ravinder Mamtani

    LicenseType:CC BY |

    预览  |  原文链接  |  全文  [ 浏览:1 下载:0  ]    

    Journal of Translational Medicine,2017年

    Hani Choudhry, Mohammed H. Al-Qahtani, Adeel G. Chaudhary, Sajjad Karim, Ashraf Dallol, Hans-Juergen Schulten, Fahad Al-Ghamdi, Awatif Jamal, Jaudah Al-Maghrabi, Fatma K. Al-Thoubaity, Adnan Merdad, Mohammed Bangash, Saleh S. Baeesa, Deema Hussein

    LicenseType:CC BY |

    预览  |  原文链接  |  全文  [ 浏览:3 下载:0  ]    

    BackgroundBreast cancer brain metastases (BCBM) develop in about 20–30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques.MethodsWe compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p < 0.05 and fold change (FC) > 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM.ResultsThe top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1, CASP14, CDC25A, DMBT1, IDH2, E2F1, MYCN, RAD51, RAD54L, and VDR. A number of small nucleolar RNAs (snoRNAs) were comparably overexpressed in BCBM and included SNORA1, SNORA2A, SNORA9, SNORA10, SNORA22, SNORA24, SNORA30, SNORA37, SNORA38, SNORA52, SNORA71A, SNORA71B, SNORA71C, SNORD13P2, SNORD15A, SNORD34, SNORD35A, SNORD41, SNORD53, and SCARNA22. The top canonical pathway was entitled, role of BRCA1 in DNA damage response. Network analysis revealed key nodes as Akt, ERK1/2, NFkB, and Ras in a predicted activation stage. Downregulated genes in a data set that was shared between BCBM and prBT comprised, e.g. BC cell line invasion markers JUN, MMP3, TFF1, and HAS2. Important cancer genes affected by CNVs included TP53, BRCA1, BRCA2, ERBB2, IDH1, and IDH2. WES detected numerous mutations, some of which affecting BC associated genes as CDH1, HEPACAM, and LOXHD1.ConclusionsUsing complementary molecular genetic techniques, this study identified shared and unshared molecular events in three highly aberrant BCBM emphasizing the challenge to detect new molecular biomarkers and targets with translational implications. Among new findings with the capacity to gain clinical relevance is the detection of overexpressed snoRNAs known to regulate some critical cellular functions as ribosome biogenesis.